Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 10 | 2026 | 1273 | 1.390 |
Why?
|
| CRISPR-Cas Systems | 4 | 2026 | 316 | 1.130 |
Why?
|
| Graft vs Host Disease | 5 | 2026 | 688 | 1.050 |
Why?
|
| Oligonucleotides | 1 | 2025 | 94 | 0.900 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 17 | 0.580 |
Why?
|
| Periosteum | 1 | 2019 | 32 | 0.570 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 607 | 0.480 |
Why?
|
| Bacterial Proteins | 3 | 2026 | 947 | 0.470 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 351 | 0.460 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 470 | 0.410 |
Why?
|
| Signal Transduction | 1 | 2025 | 4645 | 0.380 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 154 | 0.380 |
Why?
|
| Organ Transplantation | 2 | 2025 | 170 | 0.380 |
Why?
|
| Gene Editing | 2 | 2026 | 236 | 0.380 |
Why?
|
| Graft Rejection | 2 | 2025 | 556 | 0.340 |
Why?
|
| Nucleic Acid Conformation | 2 | 2026 | 177 | 0.270 |
Why?
|
| Transplantation Conditioning | 4 | 2023 | 327 | 0.240 |
Why?
|
| Endonucleases | 1 | 2026 | 53 | 0.240 |
Why?
|
| HEK293 Cells | 2 | 2025 | 800 | 0.240 |
Why?
|
| Transplantation, Haploidentical | 1 | 2026 | 20 | 0.240 |
Why?
|
| Dinucleoside Phosphates | 1 | 2025 | 12 | 0.230 |
Why?
|
| Deoxyribonucleases | 1 | 2025 | 21 | 0.230 |
Why?
|
| Adenylyl Cyclases | 1 | 2025 | 45 | 0.230 |
Why?
|
| Immune Evasion | 1 | 2025 | 38 | 0.230 |
Why?
|
| Donor Selection | 1 | 2026 | 59 | 0.230 |
Why?
|
| Caspases | 1 | 2025 | 152 | 0.220 |
Why?
|
| Cell Death | 1 | 2025 | 226 | 0.220 |
Why?
|
| Peptide Hydrolases | 1 | 2025 | 131 | 0.220 |
Why?
|
| Streptococcus pyogenes | 1 | 2025 | 81 | 0.220 |
Why?
|
| Bacteriophages | 1 | 2025 | 101 | 0.210 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2024 | 9 | 0.210 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 26 | 0.200 |
Why?
|
| Endodeoxyribonucleases | 1 | 2024 | 47 | 0.200 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 49 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 57 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 130 | 0.180 |
Why?
|
| Models, Molecular | 1 | 2025 | 1060 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 499 | 0.180 |
Why?
|
| Bacteria | 1 | 2025 | 521 | 0.170 |
Why?
|
| RNA | 1 | 2024 | 509 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2025 | 397 | 0.170 |
Why?
|
| Databases, Genetic | 1 | 2024 | 502 | 0.170 |
Why?
|
| Child | 11 | 2026 | 26171 | 0.160 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 82 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2022 | 499 | 0.150 |
Why?
|
| DNA | 1 | 2025 | 1398 | 0.150 |
Why?
|
| Humans | 18 | 2026 | 130055 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2024 | 985 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 306 | 0.140 |
Why?
|
| Acute Disease | 1 | 2022 | 1153 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 950 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2026 | 15005 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2025 | 1589 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 332 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2019 | 184 | 0.130 |
Why?
|
| Young Adult | 6 | 2026 | 9978 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 870 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 383 | 0.110 |
Why?
|
| Adolescent | 7 | 2026 | 20797 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1707 | 0.100 |
Why?
|
| Graft Survival | 2 | 2025 | 462 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17538 | 0.100 |
Why?
|
| Alemtuzumab | 2 | 2023 | 89 | 0.090 |
Why?
|
| Tissue and Organ Procurement | 2 | 2025 | 253 | 0.090 |
Why?
|
| Neuroblastoma | 1 | 2017 | 547 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 758 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 6064 | 0.080 |
Why?
|
| Adult | 6 | 2026 | 30999 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3677 | 0.070 |
Why?
|
| Infant | 4 | 2026 | 13266 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12821 | 0.070 |
Why?
|
| Female | 6 | 2026 | 70227 | 0.070 |
Why?
|
| Risk Factors | 3 | 2026 | 10956 | 0.060 |
Why?
|
| Survival Rate | 2 | 2025 | 2106 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 2974 | 0.060 |
Why?
|
| DNA Cleavage | 1 | 2025 | 10 | 0.060 |
Why?
|
| Time Factors | 2 | 2025 | 6165 | 0.060 |
Why?
|
| Nucleotide Motifs | 1 | 2025 | 51 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 20816 | 0.060 |
Why?
|
| Siblings | 1 | 2026 | 201 | 0.050 |
Why?
|
| RNA, Ribosomal | 1 | 2024 | 48 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2025 | 222 | 0.050 |
Why?
|
| Male | 6 | 2026 | 64375 | 0.050 |
Why?
|
| Proteolysis | 1 | 2025 | 199 | 0.050 |
Why?
|
| Ribosomes | 1 | 2024 | 123 | 0.050 |
Why?
|
| Encyclopedias as Topic | 1 | 2024 | 5 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6401 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 11 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2023 | 25 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1264 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 148 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3655 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2025 | 645 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 93 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 668 | 0.040 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.040 |
Why?
|
| Phylogeny | 1 | 2024 | 684 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 253 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 72 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 171 | 0.040 |
Why?
|
| Middle Aged | 3 | 2025 | 28303 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1475 | 0.040 |
Why?
|
| Age Factors | 1 | 2026 | 2822 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 430 | 0.030 |
Why?
|
| Prevalence | 1 | 2025 | 2686 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5164 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4845 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 3713 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1325 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1112 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1212 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 18160 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 33660 | 0.010 |
Why?
|